Drug intelligence / Profile preview

YJF-008

Development stage: Preclinical
Lead developer: Hanwha Pharma
Administration: Oral

Overview

YJF-008 is an investigational drug candidate being developed by Han Wha Pharma for the treatment of respiratory system disorders. As of early 2024, the program is in the preclinical stage, specifically focusing on research and formulation development. Detailed information regarding its specific molecular target, mechanism of action, or chemical structure has not been publicly disclosed by the developer. The candidate is part of Han Wha Pharma's research and development pipeline, which includes both new chemical entities and incrementally modified drugs aimed at addressing unmet needs in respiratory health.

Beyond the preview

Go deeper on YJF-008.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YJF-008.

Explore the full profile